Skip to search formSkip to main contentSkip to account menu

Mycophenolic Acid 360 MG Delayed Release Oral Tablet [Myfortic]

Known as: MYCOPHENOLATE SODIUM 360 mg ORAL TABLET, DELAYED RELEASE [Myfortic], Myfortic 360 MG Delayed Release Oral Tablet 
National Institutes of Health

Related topics

Related topics

15 relations
CrospovidoneDelayed Release Oral TabletMagnesium stearateMycophenolic Acid

Broader (1)

Myfortic Pill

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Enteric-Coated Mycophenolate Sodium
SummaryAbstractEnteric-coated mycophenolate sodium (Myfortic®) is a reversible, noncompetitive inosine monophosphate… 
2010
2010
First experience with enteric-coated mycophenolate sodium (Myfortic®) in severe recalcitrant adult atopic dermatitis: an open label study
2006
2006
Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
BACKGROUND To date, there are no data on long-term use of enteric-coated mycophenolate sodium (EC-MPS; myfortic) from time of… 
Review
2006
Review
2006
Enteric-coated Mycophenolate Sodium (myfortic®): An Overview of Current and Future Use in Transplantation
Mycophenolic acid (MPA) exerts a potent immunosuppressive effect via a number of distinct mechanisms. Use of the mycophenolate… 
2004
2004
Assessment Of Two Strategies Of Neoral® Administration, Early Versus Delayed, On Renal Function And Efficacy In De Novo Renal Transplant Patients Receiving Myfortic®, Steroids And Anti-il2r…
2004
2004
Safety And Efficacy Of Reduced Or Full Dose Of Cyclosporine (neoral®) In Combination With Mycophenolatesodium (myfortic®), Basiliximab (simulect®), And Steroids In De Novo Kidney Transplant…
2004
2004
Six month data of a 12-month, single-blind, randomized, parallel group, multicenter study to investigate the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) compared…
2004
2004
Safety And Tolerability Of Myfortic® In Combination With Steroids And Two Regimen Of Neoral®, In De Novo Kidney Transplant Recipients: 6 Months Interim Results. A Randomized, Multicentre, Open…
2004
2004
LONG-TERM SAFETY AND EFFICACY AFTER CONVERSION FROM MYCOPHENOLATE MOFETIL (MMF) TO ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS, MYFORTIC®)
2004
2004
ABSORPTION OF MYFORTIC® (ENTERIC COATED MYCOPHENOLATE SODIUM) IS PROPORTIONAL OVER A WIDE DOSE RANGE
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)